Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell therapy SYNCAR-100 targets stubborn leukemia in early trial

NCT ID NCT07429461

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated Jun 16, 2026 · Updated 18 times

Summary

This early study tests a new treatment called SYNCAR-100 for adults with a type of leukemia (B-ALL) that has come back or not responded to standard therapy. The treatment is given once a week for four weeks. The main goals are to check safety and see if it helps control the disease. Up to 16 people will take part, and they will be followed for at least a year to monitor health and survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The first affiliated hospital of medical college of zhejiang university

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA